MindImmune Awarded Grant to Accelerate IND-Enabling Studies through Rhode Island Life Science Hub

MindImmune Therapeutics announced it has been awarded a grant by Rhode Island Life Science Hub to accelerate the company’s preclinical development work on MITI-101. MITI-101 is under development for the treatment of mild-to-moderate Alzheimer’s disease.